Tumor Promoting Function of DUSP10 in Non-Small Cell Lung Cancer Is Associated With Tumor-Promoting Cytokines

Overview

Journal Immune Netw

Specialty Allergy & Immunology

Date 2023 Sep 6

PMID 37670811

Authors

Xing Wei

Chin Wen Png

Madhushanee Weerasooriya

Heng Li

Chenchen Zhu

Guiping Chen

Chuan Xu

Yongliang Zhang

Xiaohong Xu

Affiliations

Soon will be listed here.

Abstract

Lung cancer, particularly non-small cell lung cancer (NSCLC) which contributes more than 80% to totally lung cancer cases, remains the leading cause of cancer death and the 5-year survival is less than 20%. Continuous understanding on the mechanisms underlying the pathogenesis of this disease and identification of biomarkers for therapeutic application and response to treatment will help to improve patient survival. Here we found that a molecule known as DUSP10 (also known as MAPK phosphatase 5) is oncogenic in NSCLC. Overexpression of DUSP10 in NSCLC cells resulted in reduced activation of ERK and JNK, but increased activation of p38, which was associated with increased cellular growth and migration. When inoculated in immunodeficient mice, the DUSP10-overexpression NSCLC cells formed larger tumors compared to control cells. The increased growth of DUSP10-overexpression NSCLC cells was associated with increased expression of tumor-promoting cytokines including IL-6 and TGFβ. Importantly, higher DUSP10 expression was associated with poorer prognosis of NSCLC patients. Therefore, DUSP10 could severe as a biomarker for NSCLC prognosis and could be a target for development of therapeutic method for lung cancer treatment.

References

Greenberg A, Basu S, Hu J, Yie T, Rom W, Lee T . Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol. 2002; 26(5):558-64. DOI: 10.1165/ajrcmb.26.5.4689. View

Canovas B, Igea A, Sartori A, Gomis R, Paull T, Isoda M . Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells. Cancer Cell. 2018; 33(6):1094-1110.e8. DOI: 10.1016/j.ccell.2018.04.010. View

Caunt C, Keyse S . Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J. 2012; 280(2):489-504. PMC: 3594966. DOI: 10.1111/j.1742-4658.2012.08716.x. View

Low H, Wong Z, Wu B, Kong L, Png C, Cho Y . DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death. Nat Commun. 2021; 12(1):2284. PMC: 8052345. DOI: 10.1038/s41467-021-22638-7. View

Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L . p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet. 2007; 39(6):741-9. DOI: 10.1038/ng2033. View

Liu S, Yuan S, Wu H, Liu J, Huang C . The Clinical Research of Serum VEGF, TGF-β1, and Endostatin in Non-small Cell Lung Cancer. Cell Biochem Biophys. 2014; 72(1):165-9. DOI: 10.1007/s12013-014-0431-5. View

Zhang Y, Blattman J, Kennedy N, Duong J, Nguyen T, Wang Y . Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature. 2004; 430(7001):793-7. DOI: 10.1038/nature02764. View

Bade B, Dela Cruz C . Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2020; 41(1):1-24. DOI: 10.1016/j.ccm.2019.10.001. View

Low H, Zhang Y . Regulatory Roles of MAPK Phosphatases in Cancer. Immune Netw. 2016; 16(2):85-98. PMC: 4853501. DOI: 10.4110/in.2016.16.2.85. View

10.

Liu H, Zhang M, Xu S, Zhang J, Zou J, Yang C . HOXC8 promotes proliferation and migration through transcriptional up-regulation of TGFβ1 in non-small cell lung cancer. Oncogenesis. 2018; 7(2):1. PMC: 5833702. DOI: 10.1038/s41389-017-0016-4. View

11.

Png C, Weerasooriya M, Guo J, James S, Poh H, Osato M . DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis. Oncogene. 2015; 35(2):206-17. DOI: 10.1038/onc.2015.74. View

12.

Takahashi M, Okamoto Y, Kato Y, Shirahama H, Tsukahara S, Sugimoto Y . Activating mutations in EGFR and PI3K promote ATF4 induction for NSCLC cell survival during amino acid deprivation. Heliyon. 2023; 9(4):e14799. PMC: 10070656. DOI: 10.1016/j.heliyon.2023.e14799. View

13.

Liu C, Yang L, Xu H, Zheng S, Wang Z, Wang S . Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Med. 2022; 20(1):187. PMC: 9102328. DOI: 10.1186/s12916-022-02356-7. View

14.

Zappa C, Mousa S . Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016; 5(3):288-300. PMC: 4931124. DOI: 10.21037/tlcr.2016.06.07. View

15.

Li J, Shen C, Wang X, Lai Y, Zhou K, Li P . Prognostic value of TGF-β in lung cancer: systematic review and meta-analysis. BMC Cancer. 2019; 19(1):691. PMC: 6631541. DOI: 10.1186/s12885-019-5917-5. View

16.

An J, Gu Q, Cao L, Yang H, Deng P, Hu C . Serum IL-6 as a vital predictor of severe lung cancer. Ann Palliat Med. 2021; 10(1):202-209. DOI: 10.21037/apm-20-2229. View

17.

da Cunha Santos G, Shepherd F, Tsao M . EGFR mutations and lung cancer. Annu Rev Pathol. 2010; 6:49-69. DOI: 10.1146/annurev-pathol-011110-130206. View

18.

Tong X, Wang S, Lei Z, Li C, Zhang C, Su Z . MYOCD and SMAD3/SMAD4 form a positive feedback loop and drive TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer. Oncogene. 2020; 39(14):2890-2904. DOI: 10.1038/s41388-020-1189-4. View

19.

Kozaki K, Miyaishi O, Tsukamoto T, Tatematsu Y, Hida T, Takahashi T . Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res. 2000; 60(9):2535-40. View

20.

Prior I, Lewis P, Mattos C . A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012; 72(10):2457-67. PMC: 3354961. DOI: 10.1158/0008-5472.CAN-11-2612. View